Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and common Gram-negative organisms. We evaluated the activity of ceftaroline and various antimicrobial agents against S. aureus isolates according to patient age. A total of 2143 consecutive unique patient strains of clinical significance were collected between January and December 2010 from 65 US medical centers as part of the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Program. Ceftaroline and various comparator agents were tested by reference Clinical and Laboratory Standards Institute broth microdilution methods. Ceftaroline was consistently active against methicillin-susceptible S. aureus (MSSA) (MIC 50 , 0.25 μg/mL; MIC 90 , 0.25 μg/mL; 100.0% susceptible) and MRSA (MIC 50 , 0.50 μg/mL, MIC 90 , 1 μg/mL; 98.4% susceptible) from all age groups. In general, resistance rates to erythromycin, clindamycin, and levofloxacin were higher in the population aged ≥65 years, whereas resistance rates to clindamycin and levofloxacin were lowest among isolates from patients aged 6-17 years. When tested against MSSA, levofloxacin resistance was higher among isolates from patients aged ≥65 years (16.1%) than among isolates from the other age groups (6.1%-10.5%), and ceftaroline was generally 16-fold more active than ceftriaxone (MIC 50 , 4 μg/mL; MIC 90 , 4 μg/mL; 97.9% susceptible overall). Ceftaroline (MIC 50 , 0.50 μg/mL; MIC /90 , 1 μg/ mL), daptomycin (MIC 50 , 0.25 μg/mL; MIC 90 , 0.5 μg/mL), linezolid (MIC 50 , 1 μg/mL; MIC 90 , 1 μg/mL), and vancomycin (MIC 50 , 1 μg/mL ; MIC 90 , 1 μg/mL) were the most active compounds tested against MRSA strains, and the activity of these compounds did not vary significantly among the age groups. In contrast, susceptibility rates to clindamycin and levofloxacin varied from 94.0% and 60.7% (aged 6-17 years), respectively, to only 57.6% and 15.1% (aged ≥65 years), respectively, among MRSA strains. The results of this study showed major differences in the susceptibility rates to clindamycin and levofloxacin according to patient age group. The results also indicate that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independent of patient age group.
antimicrobial susceptibility of the organism, indication for surgery and/or antibacterial therapy, and, if the latter is chosen, type and length of therapy [7] . Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against resistant Gram-positive organisms, including MRSA; multidrug-resistant strains of Streptococcus pneumoniae; and common Gram-negative organisms, including wild-type Enterobacteriaceae [8, 9] . Ceftaroline fosamil is approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia [10] . As part of the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Program, a global ceftaroline surveillance study, we evaluated the activity of ceftaroline and various antimicrobial agents against US S. aureus isolates analyzed according to patient age groups.
MATERIALS AND METHODS

Organism Collection
A total of 2143 consecutive unique patient strains of clinical significance were collected between January and December 2010 from 65 US medical centers as part of the AWARE program. The isolates were collected primarily from bloodstream infections, ABSSSIs, and respiratory tract infections in hospitalized patients, according to a common surveillance design. The isolates were identified locally and forwarded to a central monitoring laboratory ( JMI Laboratories, North Liberty, Iowa) for confirmation of species identification, when necessary, and reference antimicrobial susceptibility testing. Antimicrobial susceptibility results were analyzed according to patient age group as follows: aged ≤5 years: 426 strains; aged 6-17 years: 183 strains; aged 18-49 years: 506 strains; aged 50-64 years: 508 strains; and aged ≥65 years: 520 strains.
Susceptibility Testing
Ceftaroline and various comparator agents were tested by Clinical and Laboratory Standards Institute broth microdilution methods in validated microdilution panels manufactured by ThermoFisher Inc. (formerly TREK Diagnostics Systems) [11] . Clinical and Laboratory Standards Institute interpretive criteria were used to categorize the isolates as susceptible, intermediate, and resistant [12] . A ceftaroline susceptibility breakpoint of ≤1 μg/mL was established by the FDA for S. aureus and applied in this study [10] . The S. aureus ATCC 29213 quality control strain was concurrently tested [12] .
RESULTS
Antimicrobial activities of ceftaroline and comparator agents by age group are summarized in Table 1 . The MRSA rates were slightly higher in isolates from children aged ≤5 years of age (52.6%) and adults aged ≥65 years of age (52.1%) than in isolates from the other age groups (45.9%-49.4%). Ceftaroline was consistently active against isolates from all age groups, with susceptibility rates of 98.8%-100.0%. Resistance rates to erythromycin, clindamycin, and levofloxacin were substantially higher in adults aged ≥65 years, whereas resistance to clindamycin and levofloxacin were lowest in those aged 6-17 years. The activities of tetracycline and trimethoprim/sulfamethoxazole were more consistent among the age groups. All isolates were susceptible to linezolid and vancomycin, and only 3 strains were nonsusceptible to daptomycin; all 3 were MRSA from patients aged ≥50 years.
Methicillin-susceptible S. aureus (MSSA) strains showed high rates of susceptibility to the antimicrobial agents tested except erythromycin (27.2%-35.4% resistance) and levofloxacin (6.1%-16.1% resistance). Levofloxacin resistance was higher among isolates from patients aged ≥65 years (16.1%) than among isolates from the other age groups (6.1%-10.5%). Ceftaroline (MIC 50 , 0.25 μg/mL; MIC 90 , 0.25 μg/mL; 100.0% susceptible) was 16-fold more active than ceftriaxone (MIC 50 , 4 μg/mL; MIC 90 , 4 μg/mL; 97.9% susceptible overall) when tested against MSSA strains (data not shown).
Ceftaroline (MIC 50 , 0.5 μg/mL; MIC 90 , 1 μg/mL; 98.4% susceptible overall), daptomycin (MIC 50 , 0.25 μg/mL; MIC 90 , 0.5 μg/mL; 99.7% susceptible), linezolid (MIC 50 , 1 μg/mL; MIC 90 , 1 μg/mL; 100.0% susceptible), and vancomycin (MIC 50 , 1 μg/mL; MIC 90 , 1 μg/mL; 100.0% susceptible) were the most active compounds tested against MRSA strains, and the activity of these compounds did not vary among the age groups (Table 1) . Trimethoprim/sulfamethoxazole (95.6%-100.0% susceptible) and tetracycline (90.4%-97.9% susceptible) showed good in vitro activity against MRSA strains, whereas erythromycin (5.2%-14.9% susceptible) and levofloxacin (15.1%-60.7% susceptible) exhibited limited activity against these organisms. Susceptibility to clindamycin and levofloxacin varied from 94.0% and 60.7% (aged 6-17 years), respectively to only 57.6% and 15.1% (≥65 years of age), respectively, among MRSA strains. Table 2 displays ceftaroline MIC distributions for MSSA and MRSA strains stratified by patient age groups. Ceftaroline was active against MSSA (MIC 50 , 0.25 μg/mL; MIC 90 , 0.25 μg/mL; highest MIC value of 0.50 μg/mL) and MRSA (MIC 50 , 0.5 μg/mL; MIC 90 , 1 μg/mL; highest MIC value of 2 μg/mL). All MSSA strains were highly susceptible to ceftaroline. Among MRSA infections, ceftaroline susceptibility rates varied from 97.6% (aged 50-64 years) to 100.0% (aged 6-17 years). Although MRSA strains were generally susceptible to ceftaroline across all age groups (98.4% overall), MRSA isolates from patients aged ≤17 years (age groups ≤5 and 6-17 years) exhibited ceftaroline MIC values slightly lower (81.7%-88.1% inhibited at ≤0.5 µg/mL) than those from patients aged ≥18 years (age groups 18-49, 50-64, and ≥65 years; 72.2%-56.1% inhibited at ≤0.5 µg/mL). Sixteen of 17 ceftaroline nonsusceptible strains were MRSA isolates from patients aged ≥18 years (Table 2) .
DISCUSSION
Staphylococcus aureus is an extraordinarily adaptable pathogen with a proven ability to develop antimicrobial resistance [13] .
Methicillin-resistant S. aureus, which until recently was regarded as almost exclusively a hospital-associated pathogen, has been increasingly identified as a cause of communityonset infections [2, 14, 15] . Furthermore, CA-MRSA clones have infiltrated hospitals and are rapidly replacing the traditional hospital-acquired MRSA [16] . Due to particular characteristics that are not completely understood, the USA300 clone has been very successful epidemiologically, and the high prevalence of MRSA in some geographic areas has been associated with increased prevalence of CA-MRSA in healthcare facilities [6] . In addition, although the initial CA-MRSA strains were more susceptible to antimicrobial agents than traditional hospital-acquired MRSA strains, variants of USA300 with multidrug resistance patterns have more recently been identified [17, 18] . In summary, major changes in the epidemiology and susceptibility patterns of S. aureus has been observed in recent years. Because initial antimicrobial therapy is usually selected empirically, results of large multicenter surveillance programs, such as the AWARE Program, are valuable to guide appropriate selection of antimicrobial treatment [7, 13, 19] . Although much has been reported about the antimicrobial susceptibility of S. aureus, considerably less is understood regarding resistance profile patterns according to patient age group [20] . In the present study, we evaluated 2143 consecutive unique patient S. aureus strains from 65 medical centers across the United States. Resistance rates were generally higher among isolates from patients aged ≥65 years and lowest among isolates from patients aged 6-17 years. Higher resistance rates among isolates from patients aged ≥65 years were most evident for levofloxacin (50.8% vs 20.2%-38.8% for the other age groups) and clindamycin (25.6% vs 4.4%-20.1% for the other age groups) ( Table 1 ).
The lowest rates of resistance to levofloxacin were found among the youngest patients, those aged ≤17 years of age (aged ≤5 years, 33.8%; aged 6-17 years, 20.2%). Lower rates of fluoroquinolone resistance among young patients have been reported by other investigators and reflect the limited applications of the fluoroquinolones to these patients [21] . Interestingly, resistance to clindamycin was also lower among isolates from patients aged ≤5 years (10.6%) and aged 6-17 years (4.4%), especially among MRSA strains (17.4% and 6.0% among isolates from patients aged ≤5 years and aged 6-17 years, respectively). Differences in clindamycin susceptibility were most prominent for the MRSA strains, with 6.0% resistance in patients aged 6-17 years and 42.4% resistance in patients aged ≥65 years. These results indicate that clindamycin may remain an option for treatment of certain MRSA infections in young patients but has certainly very limited use in the adult population, especially the elderly.
As expected, daptomycin, linezolid, and vancomycin were consistently active against MSSA and MRSA strains across all age groups. Notably, ceftaroline exhibited potency (lowest MIC 90 values) and spectrum similar to these well-established antistaphylococcal agents. The results of this study clearly demonstrated that ceftaroline is highly active against MSSA and MRSA strains isolated from US medical centers, independent of patient age group. In choosing the appropriate antimicrobial agent for an infection, a number of factors must be considered, including the identification and antimicrobial susceptibility of the infecting organism, the site of the infection (for antimicrobial therapy to be active, an adequate concentration of the drug must be delivered to the site of infection), and the safety and tolerability of the drug. The age of the patient is also a major factor to be considered because the metabolism, excretion, tolerability, and side effects of the antimicrobial agent are closely related to patient age. The cephalosporin class of antimicrobial agents remains the most frequently prescribed class of antimicrobials in the United States and worldwide and has maintained a favorable record of safety and tolerability in all patient age groups [22, 23] . Adverse effects and laboratory findings from the ceftaroline clinical trials were consistent with those seen with other drugs in the cephalosporin class, without clinically significant safety concerns [24, 25] .
In summary, the potent in vitro activity of ceftaroline against a large collection of contemporary clinical strains of S. aureus documented here, coupled with an excellent safety profile and clinical efficacy previously reported [9, [24] [25] [26] [27] , indicates that ceftaroline fosamil represents a valuable addition to the armamentarium of antimicrobial agents available to clinicians for the treatment of S. aureus infections, including those caused by MRSA in any patient age group.
Notes
